Ellie’s Law
Summary
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2678 authorizes zero dollars — no funding exists for research or procurement
- 2.Bill is at earliest stage (referred to committee) with no hearings scheduled
- 3.Companion bill in Senate increases passage probability but timeline is measured in years
- 4.Any market impact for MDT, TMO, ILMN, DGX requires future appropriation — not this bill
Market Implications
No near-term market impact. MDT at $79.22 (approaching 52-week low of $78.91) has been affected by broader medtech headwinds, not this bill. TMO at $469.51 and ILMN at $123.58 trade on earnings and sector trends. DGX at $192.76 is similarly driven by healthcare utilization cycles, not early-stage research authorization bills. Investors should not allocate capital based on Ellie's Law until it advances through committee and a specific funding amount is attached.
Full Analysis
Ellie's Law (HR2678) was introduced on April 7, 2025, and referred to the House Committee on Energy and Commerce. The bill directs the National Institute of Neurological Disorders and Stroke (NINDS) to conduct and support comprehensive research on unruptured intracranial aneurysms, develop diagnostics and treatments, and create a public education campaign. Critically, the bill authorizes no specific dollar amount — it is a policy authorization that sets a program in law but requires a separate appropriations bill to allocate any actual funds. With 46 bipartisan cosponsors and a companion bill (S1609) in the Senate, momentum is building, but the bill remains at the very earliest legislative stage with no committee hearings or markups yet scheduled.
The money trail is zero. Authorization bills set policy ceilings but do not allocate money. Actual funding for NINDS aneurysm research would require a future appropriations bill — and even then, the amount is unspecified. The structural impact on the medical device and diagnostics sectors is purely directional and long-dated: if future appropriations materialize, NINDS could award research grants that accelerate development of neurovascular devices (MDT's flow diverters, coils) and diagnostic tools (ILMN sequencing for genetic risk, TMO research equipment, DGX lab testing). But no contracts or revenues are guaranteed by this bill.
Market data as of April 30, 2026 shows MDT at $79.22 (down 8.57% in 30 days, approaching 52-week low of $78.91), ISRG at $449.95 (down 2.39% in 30 days), TMO at $469.51 (down 4.48% in 30 days), ILMN at $123.58 (up 0.26% in 30 days), and DGX at $192.76 (down 1.64% in 30 days). These price movements reflect broader sector trends and company-specific factors, not any impact from Ellie's Law, which is too early-stage and unfunded to affect valuations.
Remaining legislative path: referral to committee (current), subcommittee review, committee markup, House floor vote, Senate companion (S1609) committee markup and floor vote, conference committee (if different versions), presidential signature, then a separate appropriations process. Even under optimistic scenarios, any tangible market impact is 2-4 years away.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Authorization for NINDS to conduct and support research on unruptured intracranial aneurysms, including diagnostics and treatment, and to develop a public education campaign.
Who must act
National Institute of Neurological Disorders and Stroke (NINDS) within the NIH
What happens
NINDS will increase grant funding for research projects studying aneurysm treatments and devices, potentially leading to new clinical protocols and expanded reimbursement pathways.
Stock impact
MDT's Neurosurgery portfolio includes aneurysm clipping and flow diversion devices (e.g., Pipeline embolization devices). Increased research funding and awareness could accelerate adoption of existing products and support pipeline development for next-generation neurovascular devices, but no dollars are authorized or appropriated currently.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Ensuring Patient Access to Critical Breakthrough Products Act
Stop Corporate Inversions Act of 2026
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
Expanding Access to Diabetes Self-Management Training Act of 2025
NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC: $16.5M Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.